Gujarat Granted Approval To 47 Ayurveda Medicine Units Last Fiscal

AHMEDABAD : Steady domestic demand and brighter prospects in the exports market have been attracting more players in the ayurvedic medicines sector in the state. Gujarat Food and Drug Control Administration (FDCA) has approved 335 new ayurvedic medicine plants in the last four years. In the last financial year, 47 plants were approved in the state, and industry experts believe that the export demand will grow further due to growing acceptance of ayurveda.

Gujarat FDCA commissioner H G Koshia said, “We have approved 335 new ayurvedic medicine plants in the state since April 2019. In Covid year 2020-21, the state registered 150 new plants; the number dropped to 25 in 2021-22.

Now again, in 2022-23, we have approved 47 new plants for ayurvedic medicines.

There has been steady demand for alternative medicines and with the state and the central governments promoting ayurveda, new investments have been coming in.”

According to sources, a small ayurvedic medicine plant requires an investment of at least Rs 3-5 crore. “Gujarat has an established pharma industry and the ecosystem for the ayurveda sector has gained tremendous strength. This is the reason many new companies are setting up their base in the state,” said an ayurvedic medicine manufacturer.

Hardik Ukani, the president of Gujarat Ayurved Aushadh Manufacturers Association (GAAMA), said, “The demand for ayurvedic medicines has increased since Covid because of increased awareness in India and abroad. Pharmaceutical companies are also foraying into the sector because of good demand. According to the data, India’s Ayush exports amounted to $1.09 billion in 2014, which has increased to more than $1.60 billion. These medicines, herbs and extracts account for nearly 80% of the Ayush exports.”

He added that Gujarat-based ayurvedic medicine manufacturers contribute around 28% of the country’s total ayurveda exports.

“We are getting bullish on the exports market because we have been witnessing an average 8% growth rate in exports for the last few years. Ayurvedic medicines are fast gaining acceptance not only for disease prevention but also treatment. So, the demand will remain high,” he added.

  • Related Posts

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’